WSI
North Dakota Workforce Safety & Insurance

Medical Policy

Prior Authorization for Brand Necessary Medications

Effective Date: 10/01/2018 Revised Date: N/A

Responsible Department: Medical Services Reviewed Date: N/A

Purpose
The purpose of this policy is to identify the circumstances under which Workforce Safety & Insurance (WSI) approves an authorization request for brand name medication in lieu of the generic equivalent.

Policy
WSI requires an injured worker complete a trial period using the generic equivalent medication prior to reviewing for authorization of the brand name medication. Upon completion of the trial period, WSI will approve an authorization request for brand name medication in lieu of the generic equivalent in the following instances:

- Documentation demonstrates an adverse reaction to the generic medication not present with the equivalent brand name product.

- Documentation demonstrates an inadequate therapeutic response to the generic medication not present with the equivalent brand name product. The documentation must contain measurable, objective evidence to support the inadequate response to the generic equivalent of the requested brand name medication.

Procedure
WSI requires a provider complete the Provider's Request for Medication Prior Authorization (M11) to request prior authorization of a brand name medication in lieu of the generic equivalent. The request for prior authorization must include documentation detailing the objective medical evidence of the adverse reaction and/or inadequate response to the generic equivalent medication. WSI issues approval for a brand name medication which is specific to the medication, strength, and dosage and is good for a maximum of one year. To renew the authorization of a brand name medication, a provider must submit the M11 on an annual basis.